Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Retailers Lose PSE Sales For Noncompliance With Combat Meth – Feinstein

This article was originally published in The Tan Sheet

Executive Summary

Sen. Dianne Feinstein, D-Calif., wants retailers to meet their requirements for training employees on compliance with provisions of the Combat Meth Act or face being cut off from receiving deliveries of OTC pseudoephedrine products

You may also be interested in...



Proposed Combat Meth Compliance Fee Would Be Waived For Many Retailers

Businesses already paying to support the Drug Enforcement Administration's Diversion Control Program would be exempt from paying an additional fee to certify they have trained employees on compliance with the Combat Meth Act, DEA says in a proposed rule

Proposed Combat Meth Compliance Fee Would Be Waived For Many Retailers

Businesses already paying to support the Drug Enforcement Administration's Diversion Control Program would be exempt from paying an additional fee to certify they have trained employees on compliance with the Combat Meth Act, DEA says in a proposed rule

Proposed Combat Meth Compliance Fee Would Be Waived For Many Retailers

Businesses already paying to support the Drug Enforcement Administration's Diversion Control Program would be exempt from paying an additional fee to certify they have trained employees on compliance with the Combat Meth Act, DEA says in a proposed rule

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel